Feedback / Questions
cannabidivarin/cannabigerolic acid (CNBX RCC-33) - CNBX Pharma
https://www.prnewswire.com/news-releases/cnbx-files-new-pct-patent-application-for-cannabinoids-based-neoadjuvant-cancer-therapy-301652147.html
Oct 18, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next